Bonk, Inc 8-K, filed Apr 5, 2022
Bonk, Inc. (BNKK)
About this 8-K
Bonk, Inc filed this 8-K on April 5, 2022, reporting on events of April 1, 2022.
Items reported
- Item 1.01: Entered into a material agreement
- Item 7.01: Regulation FD disclosure
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C., 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact name of registrant as specified in charter)
| (State
or other jurisdiction of incorporation) |
(Commission
File Number) |
(IRS
Employer Identification No.) |
(Address of principal executive offices) (Zip Code)
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
(The Nasdaq Capital Market) | ||||
(The Nasdaq Capital Market) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging
growth company
If
an emerging growth company, indicate by check mart if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 1.01. Material Agreements
On April 1, 2022, Jupiter Wellness, Inc. (the “Company”) entered into a license agreement (the “Agreement”) with Shark Defense Technologies LLC (the “Licensor”) for the exclusive worldwide intellectual property rights to formulas and production methods for jellyfish protective compounds (the “Products”) including 4 patents pending. The Agreement includes future collaboration to develop and refine additional formulas.
The grant of the license by the Licensor to the Company is for a world-wide, perpetual, irrevocable, and exclusive license to use the Products. The license comes with the right to sublicense. The Company will pay the Licensor a 6% royalty on net sales, payable in agreed upon increments not to exceed a quarterly installment. Moreover, the Company, as stated above, will have exclusive worldwide rights to the Products, so long as gross sales revenue, in the aggregate, exceeds $50,000 USD per annum.
The foregoing description of the Agreement does not purport to be complete and is qualified in its entirety by the terms and conditions of the Agreement, a copy of which is filed as Exhibit 10.1 hereto.
Item 7.01 Regulation FD Disclosure
On April 5, 2022, the Company issued a press release a copy of which is attached as Exhibit 99.1.
Cautionary Statements
This filing and attached exhibits includes “forward-looking statements.” All statements other than statements of historical facts included or incorporated herein may constitute forward-looking statements. Actual results could vary significantly from those expressed or implied in such statements and are subject to a number of risks and uncertainties. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. The forward-looking statements involve risks and uncertainties that affect our operations and financial performance. We do not undertake any duty to update any forward-looking statement except as required by law.
Item 9.01 Financial Statements and Exhibits
Exhibits
| Exhibit No. | Description | |
99.1 10.1 |
||
| 104 | Cover Page Interactive Data File (embedded with the Inline XBRL document) |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: April 5, 2022
| JUPITER WELLNESS, INC. | ||
| By: | /s/ Brian John | |
| Brian John | ||
| Chief Executive Officer | ||
Exhibit 99.1
Jupiter Wellness Launches NoStingz Jellyfish Protective Sunscreen Backed by Patent-Pending Formula in $13 B Sunscreen Market
| ● | Jupiter licenses exclusive worldwide rights for unique formulas addressing jellyfish and man o’ war stings, sea lice, and swimmer’s itch with 4 patents-pending | |
| ● | Estimated 150 million people are stung by jellyfish globally each year |
JUPITER, FL April 5, 2022 — Jupiter Wellness, Inc. (Nasdaq: JUPW) today announced the launch of NoStingz, the Company’s proprietary line of sunscreen designed to protect against jellyfish and man o’ war stings, sea lice, and swimmer’s itch all while continuing to protect ocean lovers’ skin from UVA/UVB in a range of SPFs. Jupiter has signed a license agreement with Shark Defense Technologies for the exclusive worldwide intellectual property rights to formulas and production methods for jellyfish protective compounds including 4 patents pending. The agreement includes future collaboration to develop and refine additional formulas.
According to Fortune Business Insights, the global sun care market was worth $13 billion in 2019 and is projected to reach $17 billion by 2027. In its report, Jellyfish Gone Wild!, the U.S. National Science Foundation estimates that 150 million people are stung by jellyfish each year, with about 200,000 these occurring in Florida, and many scientists believe the number of jellyfish is increasing. Jellyfish stings can vary in severity from immediate pain, swelling, itching, and tentacle print marks, to more systemic reactions such as difficulty breathing and heart problems that may be life threatening, according to the Mayo Clinic. Portuguese man ‘o war tentacles which can extend up to 100 feet contain microscopic capsules loaded with barbed tubes that deliver venom which causes pain and welts on exposed skin, the U.S. National Ocean and Atmospheric Administration reports.
Jupiter’s NoStingz line includes sprays and lotions for children and adults with SPFs ranging from 30 to 50, with more SKUs to be added in the near future. Each product’s dermatologically tested, hypoallergenic, scientifically proven, waterproof formula prevents stings from most jellyfish and sea lice, gives sunray and UV protection and is packaged in a biodegradable bottle that is non-toxic for the marine environment.
“We see a significant market for jellyfish protective sunscreen and believe NoStingz has the potential to become the dominant brand in its category. Through this exclusive licensing agreement with Shark Defense Technologies, we intend to continue development of additional formulations for an expanded product line. NoStingz complements and will benefit from our current CaniSun distribution platforms,” stated Jupiter CEO Brian John. “The large number of Portuguese man ‘o war washing up on South Florida beaches as a result of winds and tides underscores the need for NoStingz.”
For more on NoStingz or to purchase please visit:
https://canisun.com/shop/nostingz-your-barrier-of-protection-from-sun-sea/
About Jupiter Wellness
Jupiter Wellness, Inc. (Nasdaq: JUPW) is a leading developer of pharmaceutical cannabinoids focused on skincare therapeutics and treatments. The Company’s product pipeline incorporates cannabidiol (CBD) to address indications including psoriasis, eczema, burns, herpes cold sores, and skin cancer. Jupiter generates revenue from a growing line of proprietary over-the-counter skincare products including its CaniSun™ sunscreen and other wellness brands sold through www.cbdcaring.com. For additional information, please visit www.jupiterwellness.com.
| 1 |
Forward Looking Statements
This communication contains forward-looking statements regarding Jupiter Wellness, including, the anticipated timing of studies and the results and benefits thereof. You can generally identify forward-looking statements by the use of forward-looking terminology such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “explore,” “evaluate,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” or “will,” or the negative thereof or other variations thereon or comparable terminology. These forward-looking statements are based on each of the Company’s current plans, objectives, estimates, expectations, and intentions and inherently involve significant risks and uncertainties, many of which are beyond Jupiter Wellness’ control. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties and other risks and uncertainties affecting Jupiter Wellness and, including those described from time to time under the caption “Risk Factors” and elsewhere in Jupiter Wellness’ Securities and Exchange Commission (SEC) filings and reports, including Jupiter Wellness’ Annual Report on Form 10-K for the year ended December 31, 2021 and future filings and reports by Jupiter Wellness. Moreover, other risks and uncertainties of which the combined company is not currently aware may also affect each of the companies’ forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. Investors are cautioned that forward-looking statements are not guarantees of future performance. The forward-looking statements made in this communication are made only as of the date hereof or as of the dates indicated in the forward-looking statements and reflect the views stated therein with respect to future events at such dates, even if they are subsequently made available by Jupiter Wellness on its website or otherwise. Jupiter Wellness undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made.
Jupiter Wellness Media Contact:
Phone: 561-244-7100
Email: info@JupiterWellness.com
###
| 2 |
Exhibit 10.1
LICENSE AGREEMENT
“Jellyfish Protective Compounds”
THIS LICENSE AGREEMENT (the “Agreement”) is made and is effective as of the last date of signature hereto (the “Effective Date” April 1, 2022) by and between Jupiter Wellness, a Florida corporation with its principal place of business at 1061 E. Indiantown Road, Suite 110, Jupiter FL 33477 and SHARK DEFENSE TECHNOLOGIES LLC, (“LICENSOR” and together with LICENSEE, the “Parties”), a New Jersey limited liability company with its principal place of business at: PO Box 2593, Oak Ridge, NJ 07438.
WHEREAS, LICENSOR owns and/or exclusively controls certain intellectual property rights in and to U.S. Provisional Patent 63312776 [EFS ID 45058668] (the “Licensor Patent”), and to the formulae required for the production of products related to jellyfish and nematocyst sting suppression (the “Product”) and together with the Licensor Patent and other related intellectual property, the (“Licensor IP”);
WHEREAS, LICENSEE desires to obtain from LICENSOR a global license to use the Licensor Patents (the “License”) and to use the jellyfish protective compounds as described in the patent literature (“Product”); and,
WHEREAS, in consideration of the mutual promises and understandings hereinafter set forth, the parties intending to be legally bound do hereby agree as follows:
| 1. | Grant of License. Subject to the terms and conditions of this Agreement, LICENSOR grants to LICENSEE a world-wide, perpetual and irrevocable worldwide exclusive license to use, with the right to sublicense, the Licensor IP (i) to have made, use, sell, and export products relating to LICENSOR IP (the “License”). The License is granted on the Effective Date and will remain in effect in perpetuity except in cases of breach of as provided herein. |
| 2. | Intellectual Property Ownership. LICENSOR acknowledges that LICENSEE intends to incorporate the Product into some or all of its product formulas for jellyfish protective products (the “Final Formulas”) and that LICENSEE’s brand, the Final Formulas and all associated and derivative intellectual property and commercially sensitive information is solely owned by LICENSEE. LICENSOR further acknowledges that it has no ownership interest, encumbrance, lien or title in LICENSEE’s brands, the Final Formulas, LICENSEE’s trade dress, its customer lists and/or any other intellectual property or proprietary information associated with the Final Formulas. |
| 3. | Exclusivity. LICENSEE will have exclusive worldwide rights to the Product, assuming gross sales revenue in aggregate exceeds $50,000 USD per annum. |
| 4. | Royalty. LICENSEE will provide the LICENSOR a 6% royalty on net sales, payable in agreed upon increments but not to exceed a quarterly installment. This payment will remain in place as long as the Licensor IP is not assigned a “WITHDRAWN”, “ABANDONDED”, or “LAPSED” status by the US Patent and Trademark office. LICENSOR will pursue the filing of the full utility patent application before February 22, 2023. If a full US patent is not granted the terms of this license will be re-negotiated. |
| 5. | Future Collaboration. LICENSOR and LICENSEE will collaborate in the future to develop and refine additional solutions for jellyfish protection. |
| 6. | Derivative or Future Products. All derivatives of Product shall be included in the terms of this Agreement. In the event of the development of a new “recipe/formula” of the Product which demonstrates a material improvement over existing Product, LICENSOR will notify LICENSEE within 10 days and the improved formula will be immediately available for purchase by LICENSEE at a cost to be determined by LICENSEE and LICENSOR. |
| Page 1 of 5 |
| 7. | Publicity; Filming Rights. LICENSEE may use LICENSOR name for marketing and publicity purposes with written permission from LICENSOR which will not be unreasonably withheld. LICENSOR will make available to LICENSEE all of the LICENSOR’S relevant jellyfish research and testing results to aid LICENSEE in establishing credibility of PRODUCT. LICENSEE reserves the right to use any information therein for marketing and/or product claim purposes. |
| 8. | Third-Party Infringement. LICENSOR and LICENSEE agree that either Party shall notify the other within ten business days upon discovery of a potentially infringing Product that is being manufactured, sold, or otherwise disclosed by a third party. After receiving a quotation for legal expenses and after mutual agreement to assume the legal costs, the LICENSOR and LICENSEE agree to litigate on an equal basis so that both the LICENSOR and LICENSEE are responsible to pay for one-half of the legal costs and litigation expenses and receive one-half of any recovery. LICENSEE shall have the right to litigate in LICENSOR’S name at LICENSEEE’S sole expense if LICENSOR elects not to participate in legal proceedings against the third-party. LICENSOR and LICENSEE further acknowledge that it may be in both Parties interest to settle litigation by issuing non-exclusive rights to the challenging entity. |
| 9. | No Partnership or Joint Venture. This Agreement is not intended to be a partnership, joint venture, agency, or franchise relationship between the parties, and shall not be construed so as to permit LICENSEE to bind LICENSOR to any agreement or to act on behalf of LICENSOR in any way whatsoever. |
| 10. | Assignment. Neither Party may assign or transfer any rights or obligations under this Agreement without the prior written consent of the other Party. The prohibition contained in this Section shall not apply to a transfer by operation of law or assignment by a Party of this Agreement upon a “Change in Control” of that Party. A “Change in Control” means the sale or transfer of all or substantially all of the assets or all of the issued and outstanding voting stock of a Party, a merger or consolidation of a Party with a third party by which the third party has acquired, directly or indirectly, substantially all of a Party’s business, or the sale or transfer by a Party or its shareholders of a controlling equity interest in that Party. A Party as to which a Change in Control has occurred shall give the other Party prompt written notice of the occurrence of any Change in Control. This Agreement will be binding upon and inure to the benefit of each of the parties and their respective assigns or successors. No unilateral assignment or transfer of obligations under this Agreement shall relieve a party from its obligations hereunder unless expressly waived and released by the other party. |
| 11. | Termination. | |
| a | Either Party may terminate this Agreement and the License granted hereunder if the other Party materially breaches this Agreement and such breach is not cured within sixty (60) days after written notice to the breaching party of such breach. |
| b | This Agreement shall also be subject to immediate termination by either Party upon the commencement of any bankruptcy or insolvency proceeding by or against the other Party. |
| c | Upon termination of this Agreement by either Party, the LICENSEE shall have the right to complete any sales of prior purchased inventory. |
| d | Notwithstanding any termination of this Agreement, any provisions that by their terms or nature must by necessity remain in force and binding shall survive such termination. |
| e | Upon termination of this Agreement by either Party, the LICENSEE shall return all testing data, reports, and other proprietary information about the Product. |
| 12. | Governing Law. This Agreement shall be interpreted in accordance with the laws of the State of New Jersey. |
| Page 2 of 5 |
| 13. | Notice. All notices under this Agreement shall be sent via certified mail as follows: |
If to LICENSOR:
Shark Defense Technologies LLC
PO Box 2593
Oak Ridge, NJ 07438
If to LICENSEE:
Jupiter Wellness
1061
E. Indiantown Road
Suite 110
Jupiter FL 33477
| 14. | Non-Solicitation. LICENSOR shall not contact or solicit in any way the customers, buyers, representatives or other agents of LICENSEE during the term of this Agreement or for a period of two years after expiration of the Agreement except as expressly authorized by the LICENSEE and only in the specific context of that express authorization. Any breach of this provision shall entitle the LICENSEE to seek injunctive relief in any court of equity in the State of New Jersey. This restriction does not apply to the LICENSOR’s existing customers, buyers, representatives or other agents that are already using other variants of the Product under pre-existing non-exclusive terms. |
| 15. | Licensor Representations and Warranties. |
| e | LICENSOR is duly organized, validly existing, and in good standing under the laws of the state of New Jersey and has full capacity power, and authority to enter into this Agreement, to carry out its obligations hereunder, and to consummate the transactions contemplated hereby, and no other action on the part of LICENSOR is necessary to authorize the execution and delivery of this Agreement. |
| f | LICENSOR is the owner of the Licensor IP. |
| g | LICENSEE’S use of the Licensor IP pursuant to the terms of this Agreement will not infringe any patents or third-party IP rights. |
| h | LICENSEE’s use, sale and distribution of the Products will not violate any law. |
| i | The execution, delivery and performance by LICENSOR of this Agreement, and the consummation of the transactions contemplated hereby, do not and will not: (a) conflict with or result in a violation or breach of, or default under, any provision of the organizational documents of LICENSOR or (b) conflict with or result in a violation or breach of any provision of any law applicable to LICENSOR. |
| j | LICENSOR agrees that its corporate operating agreement provides provisions to safeguard the “recipe” for the Product in the event of the death of all of its officers. LICENSOR shall ensure that its successors are able to continue to create bulk product for the LICENSOR in accordance with this agreement. |
| 16. | LICENSOR will provide warranty for any product considered defective, and ineffective, and will replace any defective items at no cost to LICENSEE promptly, within the time necessary to produce, test, and requalify the replacement Product.. |
| Page 3 of 5 |
| 17. | Indemnification. LICENSOR hereby agrees to defend, indemnify and hold harmless LICENSEE and its directors, officers, employees and agents from and against any claim, judgment, settlement, liability, loss, expense, or cost of any kind (including, without limitation, reasonable legal, expert witness, and accounting fees) (each, a “Claim”) arising out of or resulting from any of the following: (i) any breach of a term, condition, representation and/or warranty made by LICENSOR hereunder; (ii) any failure on the part of LICENSOR to comply with any law, rule, regulation, ordinance or safety certification required for the Product; (iii) the negligence or willful misconduct of LICENSOR or its assigns, successors, or representatives; (iv) LICENSOR’S infringement of any third-party intellectual property rights; or (v)) any theory of strict liability in tort with regard to the Product. |
| 18. | Litigation. In the event of any controversy, claim or dispute between the parties arising out of or relating to this Agreement or the breach of this Agreement, the “prevailing party”, as that term is construed by New Jersey law, shall be entitled, in addition to such other relief as may be granted, to a reasonable sum as and for attorney’s fees and related costs, which shall be determined by the court in that litigation or in a separate action brought for that purpose. |
| 19. | Entire Agreement. This Agreement contains the entire agreement between the parties. Any prior agreements, promises, negotiations or representations not expressly set forth in this Agreement are of no force or effect. Any amendment to this Agreement shall be ineffective unless it is in writing and signed by both parties. If any term, provision, covenant or condition of the agreement is held by a court of competent jurisdiction to be invalid, void, or unenforceable, the rest of the agreement shall remain in full force and effect and shall in no way be affected, impaired or invalidated. |
| 20. | Severability and Independence of Provisions. If any provision of this Agreement is held invalid or unenforceable, that provision shall be construed, limited, modified or, if necessary, severed, to the extent necessary to eliminate its invalidity or unenforceability, and the other provisions of this Agreement shall remain unaffected. |
| 21. | Waiver. No waiver of a right under this Agreement shall be effective unless done in writing. No waiver of any right arising from any breach or failure to perform shall be a waiver of any present or future rights under this Agreement. |
| 22. | Counterparts. This Agreement may be signed by the parties in one or more counterparts, each of which shall be deemed to be an original, but which when taken together shall constitute one single agreement binding on all the parties and their executors and or assigns. |
| Page 4 of 5 |
IN WITNESS WHEREOF:
| LICENSOR: | ||
| Shark Defense Technologies, LLC | ||
 |
||
| Title | CEO | |
| Date | 4/1/2022 | |
| LICENSEE: | ||
| Jupiter Wellness | ||
 |
||
| Title | CEO | |
| Date | 4/1/2022 | |
| Page 5 of 5 |